Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Sep 27;7(39):64182-64190.
doi: 10.18632/oncotarget.11639.

Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion

Yan Fang  1 , Jiayi Wu  1 , Wei Wang  1 , Xiaochun Fei  2 , Yu Zong  1 , Xiaosong Chen  1 , Ou Huang  1 , Jianrong He  1 , Weiguo Chen  1 , Yafen Li  1 , Kunwei Shen  1 , Li Zhu  1
Affiliations
Comparative Study

Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion

Yan Fang et al. Oncotarget. .

Abstract

Background: Ductal carcinoma in situ with microinvasion (DCIS-Mi) generally has favorable prognosis, but the long-term outcomes of DCIS-Mi and the biologic evolution from ductal carcinoma in situ (DCIS), DCIS-Mi, to DCIS with T1a breast cancer (DCIS-T1a) has not been specified. The aim of our study was to explore the biological and prognostic features of DCIS-Mi, compared with pure DCIS and DCIS-T1a.

Results: After a median follow-up of 31 months, the 3-year estimated disease free survival(DFS) rate of DCIS-Mi patients was significantly lower than that of pure DCIS patients (89.5% vs 97.1%, P=0.009). Patients with DCIS-Mi or DCIS-T1a tumors had comparable 3-year estimated DFS rates (89.5% vs 94.3%, P=0.13). No significant difference in overall survival (OS) was found among different groups (99.6%, 100% and 99.1% for DCIS, DCIS-Mi and DCIS-T1a, P=0.797). In chemotherapy and trastuzumab-naive DCIS-Mi patients, human epidermal growth factor receptor2 (HER2) positivity (HR=21.8, 95%CI, 1.7-286.8, P=0.019) were independent predictor of worse DFS on multivariate analysis.

Methods: During September 2002 and December 2014, 602 breast cancer patients who underwent radical surgery were retrospectively reviewed. Three hundred and fifty-nine patients (59.6%) had pure DCIS, 84(14.0%) and 159(26.4%) were diagnosed as DCIS-Mi and DCIS-T1a. Clinico-pathological features were compared between different subgroups.

Conclusions: DCIS-Mi displayed a comparable survival to that of DCIS-T1a and a more aggressive biological nature than pure DCIS. Patients with HER2-positive DCIS-Mi had a worse survival and adjuvant chemotherapy plus target therapy needs to be further optimized in those patients.

Keywords: breast carcinoma; clinico-pathological feature; ductal carcinoma in situ; microinvasion; prognosis.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1. Disease free survival of different subgroups
Pure DCIS=Pure ductal carcinoma in situ. DCIS-Mi=Ductal carcinoma in situ with microinvasion. DCIS-T1a=Ductal carcinoma in situ with T1a breast cancer.
Figure 2
Figure 2. Overall survival of different subgroups
Pure DCIS=Pure ductal carcinoma in situ. DCIS-Mi=Ductal carcinoma in situ with microinvasion. DCIS-T1a=Ductal carcinoma in situ with T1a breast cancer.
Figure 3
Figure 3. Disease free survival of different HER2 status
HER2=human epidermal growth factor receptor 2.
See this image and copyright information in PMC

References

    1. Edge S, Byrd DR, Compton CC, Fritz GA, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7. Springer; New York: 2009.
    1. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–36. - PubMed
    1. Bianchi S, Vezzosi V. Microinvasive carcinoma of the breast. Pathol Oncol Res. 2008;14:105–11. - PubMed
    1. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96:906–20. - PubMed
    1. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443–8. - PubMed

Publication types

MeSH terms